Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus–Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial TF was detectable in 75.4% of baseline ...
A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators reveals how melanoma, the deadliest form of skin cancer, evolves to resist immunotherapy and identifies a potential ...
A protein tied to ALS and dementia may have a much bigger role in disease than scientists realized. Researchers found that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results